BACKGROUND: Cytomegalovirus (CMV) disease is a risk factor for allograft rejection in renal transplant (RTx) recipients. However, the role of asymptomatic CMV infection remains controversial. OBJECTIVES: To determine the impact of CMV disease and asymptomatic infection on biopsy-proven acute rejection (BPAR) during 12 months post-RTx. STUDY DESIGN: A total of 106 consecutive RTx recipients at risk for CMV (donor and/or recipient CMV seropositive) were followed prospectively for 12 months post-RTx. CMV activity was monitored using nested PCR from whole blood. Three-month prophylaxis with valacyclovir or ganciclovir was given to 94 patients. BPAR episodes were classified according to the Banff 97 criteria. Multivariate Cox proportional hazards model was used to estimate the effect of CMV disease, asymptomatic infection, and other covariates on BPAR. RESULTS:Asymptomatic CMV infection occurred in 23% of the patients and 10% developed CMV disease. The incidence of BPAR was 29%. CMV disease was an independent risk factor for BPAR (HR=3.0, P=0.014), while asymptomatic CMV infection was not (P=0.987). In addition to CMV disease, expanded criteria donor and donor age were independent predictors for BPAR. In univariate analysis, valacyclovir (HR=0.26, P=0.008) decreased the risk of BPAR. A similar trend was observed with ganciclovir (HR=0.42, P=0.058). Only valacyclovir remained significant in multivariate analysis (HR=0.18, P=0.044). CONCLUSIONS:CMV disease, but not asymptomatic infection, is an independent risk factor for BPAR during the first 12 months post-RTx.
RCT Entities:
BACKGROUND:Cytomegalovirus (CMV) disease is a risk factor for allograft rejection in renal transplant (RTx) recipients. However, the role of asymptomatic CMV infection remains controversial. OBJECTIVES: To determine the impact of CMV disease and asymptomatic infection on biopsy-proven acute rejection (BPAR) during 12 months post-RTx. STUDY DESIGN: A total of 106 consecutive RTx recipients at risk for CMV (donor and/or recipient CMV seropositive) were followed prospectively for 12 months post-RTx. CMV activity was monitored using nested PCR from whole blood. Three-month prophylaxis with valacyclovir or ganciclovir was given to 94 patients. BPAR episodes were classified according to the Banff 97 criteria. Multivariate Cox proportional hazards model was used to estimate the effect of CMV disease, asymptomatic infection, and other covariates on BPAR. RESULTS: Asymptomatic CMV infection occurred in 23% of the patients and 10% developed CMV disease. The incidence of BPAR was 29%. CMV disease was an independent risk factor for BPAR (HR=3.0, P=0.014), while asymptomatic CMV infection was not (P=0.987). In addition to CMV disease, expanded criteria donor and donor age were independent predictors for BPAR. In univariate analysis, valacyclovir (HR=0.26, P=0.008) decreased the risk of BPAR. A similar trend was observed with ganciclovir (HR=0.42, P=0.058). Only valacyclovir remained significant in multivariate analysis (HR=0.18, P=0.044). CONCLUSIONS:CMV disease, but not asymptomatic infection, is an independent risk factor for BPAR during the first 12 months post-RTx.
Authors: Tomas Reischig; Martin Kacer; Pavel Jindra; Ondrej Hes; Daniel Lysak; Mirko Bouda Journal: Clin J Am Soc Nephrol Date: 2014-11-25 Impact factor: 8.237
Authors: Ecaterina M Enache; Luminita S Iancu; Simona Hogas; Daniela Jitaru; Iuliu C Ivanov; Liviu Segall; Adrian C Covic Journal: Int Urol Nephrol Date: 2011-04-20 Impact factor: 2.370
Authors: Daniel S Owers; Angela C Webster; Giovanni F M Strippoli; Kathy Kable; Elisabeth M Hodson Journal: Cochrane Database Syst Rev Date: 2013-02-28
Authors: Michelle Willicombe; Jill Moss; Linda Moran; Paul Brookes; Eva Santos-Nunez; Adam G McLean; Thomas Cairns; David Taube; Terence H Cook; Candice Roufosse Journal: J Am Soc Nephrol Date: 2015-11-27 Impact factor: 10.121
Authors: Tomas Reischig; Martin Kacer; Petra Hruba; Hana Hermanova; Ondrej Hes; Daniel Lysak; Stanislav Kormunda; Mirko Bouda Journal: BMC Infect Dis Date: 2018-11-15 Impact factor: 3.090
Authors: Isabel Pérez-Flores; Jose Luis Santiago; Cristina Fernández-Pérez; Elena Urcelay; María Ángeles Moreno de la Higuera; Natividad Calvo Romero; Beatriz Rodríguez Cubillo; Ana Isabel Sánchez-Fructuoso Journal: Open Forum Infect Dis Date: 2019-07-20 Impact factor: 3.835